Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL3513621 | 0.89 | HIF1A (0.38) | HIF1AKDM1AMAOAMAOBKCNH3 | |
| Iodide SCHEMBL13280558 | 0.86 | HIF1A (0.48) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Iodide SCHEMBL1969660 | 0.82 | HIF1A (0.44) | HIF1AKDM1AMAOAMAOBTSHR | |
| Bromide SCHEMBL129506 | 0.82 | HIF1A (0.48) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL6428595 | 0.79 | HIF1A (0.44) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Iodide SCHEMBL1968748 | 0.78 | ALDH1A1 (0.35) | HIF1ATSHRALDH1A1 | |
| Iodide SCHEMBL8182049 | 0.78 | HIF1A (0.40) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Iodide SCHEMBL8182047 | 0.78 | HIF1A (0.40) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5234960 | 0.77 | HIF1A (0.43) | HIF1AKDM1AMAOAMAOBTSHR | |
| SCHEMBL8373290 | 0.77 | HIF1A (0.43) | HIF1ATSHRALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327355-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-15 | — | — | US | disclosed |
| EP-3383864-A1 | ISOINDOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017093930-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| EP-2881394-A1 | CONDENSED RING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1778678-A1 | ENANTIOSELECTIVE PROCESS | Prosidion Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| EP-1778657-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | Prosidion Ltd. (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016174-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016178-A1 | ENANTIOSELECTIVE PROCESS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | CHRM1 1894/4885CHRM3 3300/4885HIF1A 641/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | CHRM1 3630/4885CHRM3 1930/4885HIF1A 2150/4885 |
| US-20180327355-A1 | ISOINDOLINE DERIVATIVES | IRF3, EIF2AK2, MAVS | CHRM1 2921/4885CHRM3 1510/4885HIF1A 1624/4885 |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | TRPV1, TRPV2, TRPV3 | CHRM1 470/4885CHRM3 393/4885HIF1A 3787/4885 |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | CHRM1 2865/4885CHRM3 3334/4885HIF1A 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.